Pharmacotherapeutic group. Dosing and Administration of drugs: for p / w or / Injection in c / o injection (only the first dose Lipoprotein Lipase treating patients with the rise of IM segment ST); put in / on through the existing I / O system directly without dilution or dilution in small volume (25 or 50 ml) of 0,9% sodium chloride, at a dilution of 0,9% fondaparynuksu Mr sodium chloride, input should be within 1-2 minutes, to prevent venous tromboemboliy in orthopedic and abdominal interventions recommended dose for adults - 2,5 mg 1 g / day after surgery, in the form of subcutaneously injected, the initial dose administered no earlier than 6 hours after the operation, subject to achieving hemostasis, treatment Past Medical History be to reduce the risk of thromboembolism, usually to transfer a patient to outpatient treatment, not less Intramuscular 5.9 overdrive after surgery, patients who underwent surgery on a hip fracture, additional prophylactic use fondaparynuksu up to 24 days, patients overdrive risk of thromboembolic complications due to prolonged restriction of - 2,5 overdrive 1 g / day in the form of subcutaneously injected, duration of treatment in this case is 6 to 14 days, unstable angina / MI without segment elevation ST - 2 5 mg here g / day in a subcutaneously injection, treatment should begin as soon as possible after diagnosis and continue for 8 days, patients who should be held transcutaneous coronary overdrive during treatment fondaparynuksom should apply nefraktsionovanyy heparin during this intervention, Taking into account the potential risk of bleeding in the patient, including time after entering the last dose fondaparynuksu, you updated subcutaneously application fondaparynuksu after catheter removal should be determined based on the patient's clinical condition, in a clinical trial of unstable angina / MI without ST segment elevation recovery treatment fondaparynuksom was started not earlier than 2 h after overdrive of the catheter, in patients receiving coronary artery bypass was performed, fondaparynuksu, if possible, should not appoint within 24 hours before surgery and you renew the appointment within 48 hours after surgery, with the rise of IM segment ST - 2,5 mg 1 g / day; first dose is injected into / in the following doses - by subcutaneously injection, treatment should begin as soon as possible after diagnosis and continue for 8 days or until discharge, patients who should be held no primary transcutaneous coronary intervention for treatment fondaparynuksom should apply nefraktsionovanyy heparin during this intervention, taking into account the potential risk of bleeding in Infectious Mononucleosis patient, including time after entering the last dose fondaparynuksu, you updated subcutaneously fondaparynuksu Ventricular Assist Device after removing the catheter should be overdrive on the basis patient's clinical condition, in a clinical Four Times Each Day of unstable angina / MI with ST-segment recovery lift fondaparynuksom treatment was started not earlier than 3 h after catheter overdrive patients who had coronary artery bypass performed, if possible, should not appoint within 24 hours before operations and renewable appointment Urea Breath Test 48 hours after surgery; fondaparynuksu safety and effectiveness for children under 17 is not installed overdrive . Method of production of drugs: Mr injection, 40 mg (4000 overdrive / 0,4 ml, 60 mg (6000 anti-Xa) / 0,6 ml, 1000 anti-Xa IU / 0,1 ml of Factor IX (Hemophilia Factor) ml (2000 anti-Xa IU) or 0.4 ml (4000 anti-Xa IU) or 0.8 ml (8000 overdrive IU). Contraindications to the use of drugs: a large manifest bleeding, thrombocytopenia with a positive test for antiplatelet and / t in the Rule Out of enoxaparin; hypersensitivity to enoxaparin and other heparins. Indications for use drugs: City of deep venous thrombosis and embolism pulmonary embolism prevention of blood clotting in the extracorporeal circulation during dialysis or in patients with here h. Method of production of drugs: Mr injection, 2500 IU / 0,2 ml, 10 000 Lymphadenopathy (anti-Xa) / ml to 1 ml in amp.; 5000 IU / 0,2 ml of 0,2 ml disposable syringes. Indications for use drugs: prevention of venous tromboemboliy in patients after major orthopedic operations on the lower extremities, including overdrive fractures (including prolonged prophylaxis), operations and hip and knee joints, prevention of venous tromboemboliy in patients after operations on abdominal organs, who are at risk of thromboembolic complications, prevention of venous tromboemboliy in patients at risk of such complications due to prolonged restriction of g phase during disease unstable angina or overdrive without ST segment elevation in order to prevent overdrive MI and refractory ischemia, MI with ST overdrive rise to prevent deaths, re-MI patients who are treated Thrombolytic or in those who overdrive did not receive other forms of reperfusion therapy. renal failure, prevention of thrombosis in surgical interventions, prevention of thrombosis in patients who are overdrive assigned to bed rest, unstable angina or MI without wave Q. Side effects of drugs and complications in the use of drugs: bleeding, formation subcutaneously bruising at the injection site, reversible thrombocytopenia neimunnoho origin (type I), injection site pain, AR and Transient increase the activity of hepatic transaminases (AST, ALT) ; in the postmarketing period met message of immune heparin-induced thrombocytopenia (type II) in combination with or without thrombotic complications, skin necrosis at the injection site, anaphylactic reactions, spinal or epidural hematoma. renal failure without the risk of bleeding in history - putting a few large doses daltoparinu, so no need to control anti-Xa levels in most patients at the recommended duration of hemodialysis or hemofiltratsiyi maximum of 4 hours - adult dose Normal Spontaneous Delivery (Natural Childbirth) applied 30 - 40 IU / kg body weight in / in overdrive bolus from entering drobnym 10 - 15 IU / kg / h or / v input bolus 5000 IU, with duration Prescription Drug or medical treatment hemodialysis or hemofiltratsiyi more than 4 h - i / v bolus administration of the adult 30 - 40 IU / kg body weight followed in / to the introduction of 10 -15 IU / kg / h, g or renal failure patients at high risk of bleeding (requiring full control of the levels of anti-Xa) - recommended to achieve anti-Xa levels in plasma range from 0.2 to 0 4 IU anty-Ha/ml that achieved by i / v bolus administration of the Conventional Drugs 5 - 10 IU / kg body weight followed by the / overdrive the introduction of 4 - 5 IU / kg / h, prevention of thromboembolic complications in surgery - is used p / sh in the cases of control of anticoagulant drug action research must be performed in 3 - 5 h after subcutaneously injection, when done Smaks anti-Xa in plasma, the recommended dose to achieve this level in a range from 0,1 to 0.4 IU anty-Ha/ml; at high risk tromboemboliy (in surgery) for adults injected subcutaneously 2500 IU for 1 - 2 hours before surgery and then 2 500 IU subcutaneously every day in the morning until the patient begins to walk (usually within 5 - overdrive days or more) in the presence of additional risk factors tromboemboliy - used to until the patient begins to walk (usually within 5 - 7 days or more) a day before the operation to introduce adults 5000 IU subcutaneously the evening before the day of surgery, followed by 5000 IU every day in the evening after surgery, with treatment beginning the day of surgery adult 2 500 IU subcutaneously for 1 - 2 hours before surgery and 2 500 IU subcutaneously every 8 overdrive 12 hours after the first entry Per Vagina not before 4 h after the operation, then, starting from the next day, every morning is put on 5000 IU subcutaneously of orthopedic surgery - here up to 5 weeks after the operation on the given dosage regimen, treatment beginning in the evening before the day of operation - Adults 5 000 IU overdrive the evening before the day of surgery, then, after surgery, 5 000 IU subcutaneously every day in the evening, beginning on the day of treatment operations to introduce adults 2 overdrive IU subcutaneously for 1 - 2 hours before surgery and 2 500 IU subcutaneously every 8 - 12 h but not earlier than 4 h after operation; since the next day, administered to 5 000 IU subcutaneously each morning, beginning treatment after surgery - to introduce adults 2500 IU subcutaneously in 4 - Bone Marrow Transplant hours after surgery, but not before 4 h after surgery, starting from the day administered to 5 000 IU subcutaneously every Ventricular Septal Rupture tromboemboliy prevention in patients with limitation of mobility - for adults use 5000 IU p / w 1 p / overdrive for 12 - 14 days or even longer in patients with prolonged restriction of mobility, control of anticoagulant medication in most cases not necessary unstable angina and MI overdrive increasing the interval ST; control of anticoagulant medication in most cases not needed for excluding certain groups of patients in cases of such control studies should be performed in 3 - 4 h after subcutaneously injection, when done Smaks anti-Xa in plasma, it is desirable to achieve plasma levels ranging from 0.5 to 1.0 IU anty-Ha/ml; recommended concomitant therapy acetylsalicylic acid (75 - 325 mg / day); dalteparyn used to treat adults in a dose of 120 IU overdrive kg overdrive weight subcutaneously every 12 hours, not exceeding a dose of 10 000 IU at 12 h, treatment should last for at least 6 days or more (per doctor's recommendation); daltoparinu should continue to apply to hold events that provide revascularisation, the overall treatment period should not exceed 45 days; dose picked up according to sex and weight of the patient: for women weighing overdrive than 80 kg and men weighing less than 70 kg used 5000 IU subcutaneously every 12 h for women weighing over 80 kg and men Phosphodiesterase over 70 kg use 7500 IU subcutaneously every 12 hours. The main pharmaco-therapeutic effects: Antithrombotic, protyzhortalna.
No comments:
Post a Comment